Vor Biopharma (VOR) Free Cash Flow (2020 - 2026)
Vor Biopharma (VOR) reported Free Cash Flow of -$38.3 million for Q1 2026, down 23.15% year-over-year from -$49.8 million in Q1 2025, and down 61.34% on a QoQ basis from -$23.7 million in Q4 2025.
Vor Biopharma (VOR) has 7 years of Free Cash Flow data on file, last reported at -$38.3 million in Q1 2026.
- Quarterly Free Cash Flow fell 23.15% year-over-year to -$38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$150.8 million (down 50.28% YoY) and the FY2025 annual result came in at -$143.7 million, down 43.81% from the prior year.
- Free Cash Flow fell to -$38.3 million in Q1 2026 per VOR's latest filing, from -$23.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$17.6 million in Q3 2022 and bottomed at -$53.3 million in Q3 2025.
- The 5-year median for Free Cash Flow is -$24.3 million (2023), against an average of -$27.5 million.
- The widest annual swing landed in 2024, when Free Cash Flow climbed 15.1%; it then slumped 128.6% in 2025.
- Tracing VOR's Free Cash Flow over 5 years: stood at -$18.3 million in 2022, then tumbled by 31.13% to -$24.0 million in 2023, then declined by 0.42% to -$24.1 million in 2024, then rose by 1.75% to -$23.7 million in 2025, then sank by 61.34% to -$38.3 million in 2026.
- Per Business Quant, the three latest VOR Free Cash Flow figures stand at -$38.3 million (Q1 2026), -$23.7 million (Q4 2025), and -$53.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | -38.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.26 Mn |
| Mar 31, 2026 | -38.26 Mn |
| Dec 31, 2025 | -23.71 Mn |
| Dec 31, 2025 | -23.71 Mn |
| Sep 30, 2025 | -53.31 Mn |
| Sep 30, 2025 | -53.31 Mn |
| Jun 30, 2025 | -35.57 Mn |
| Jun 30, 2025 | -35.57 Mn |
| Mar 31, 2025 | -31.07 Mn |
| Mar 31, 2025 | -31.07 Mn |
| Dec 31, 2024 | -24.14 Mn |
| Dec 31, 2024 | -24.14 Mn |
| Sep 30, 2024 | -23.32 Mn |
| Sep 30, 2024 | -23.32 Mn |
| Jun 30, 2024 | -21.86 Mn |
| Jun 30, 2024 | -21.86 Mn |
| Mar 31, 2024 | -30.58 Mn |
| Mar 31, 2024 | -30.58 Mn |
| Dec 31, 2023 | -24.03 Mn |
| Dec 31, 2023 | -24.03 Mn |
| Sep 30, 2023 | -27.47 Mn |
| Sep 30, 2023 | -27.47 Mn |
| Jun 30, 2023 | -24.59 Mn |
| Jun 30, 2023 | -24.59 Mn |
| Mar 31, 2023 | -24.27 Mn |
| Mar 31, 2023 | -24.27 Mn |
| Dec 31, 2022 | -18.33 Mn |
| Dec 31, 2022 | -18.33 Mn |
| Sep 30, 2022 | -17.63 Mn |
| Sep 30, 2022 | -17.63 Mn |
| Jun 30, 2022 | -22.78 Mn |
| Jun 30, 2022 | -22.78 Mn |
| Mar 31, 2022 | -26.44 Mn |
| Mar 31, 2022 | -26.44 Mn |
| Dec 31, 2021 | -18.76 Mn |
| Dec 31, 2021 | -18.76 Mn |
| Sep 30, 2021 | -17.98 Mn |
| Sep 30, 2021 | -17.98 Mn |
| Jun 30, 2021 | -18.51 Mn |
| Jun 30, 2021 | -18.51 Mn |
| Mar 31, 2021 | -17.80 Mn |
| Mar 31, 2021 | -17.80 Mn |
| Dec 31, 2020 | -11.39 Mn |
| Dec 31, 2020 | -11.39 Mn |
| Sep 30, 2020 | -9.83 Mn |
| Sep 30, 2020 | -9.83 Mn |
| Jun 30, 2020 | -8.88 Mn |
| Jun 30, 2020 | -8.88 Mn |
| Mar 31, 2020 | -6.63 Mn |
| Mar 31, 2020 | -6.63 Mn |